Drug Profile
Research programme: multiple sclerosis therapeutics - Apitope/Merck Serono
Alternative Names: ATX-MS-2; ATX-MS-3Latest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Apitope Technology
- Class Peptides; Vaccines
- Mechanism of Action Immunomodulators; Interleukin 10 stimulants; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Multiple-sclerosis in United Kingdom
- 13 Oct 2015 Preclinical trials in Multiple sclerosis in United Kingdom (unspecified route)
- 08 Jul 2011 Early research in Multiple sclerosis in United Kingdom (unspecified route)